AstraZeneca in $6 Billion Deal for Cancer Drug Prospect
- Posted by ISPE Boston
- On August 6, 2020
AstraZeneca and Daiichi Sankyo have entered into a global development and commercialization agreement for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC). DS-1062 is currently in phase 1 clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 […]
Read More